These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 5820999)

  • 21. L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
    Mars H; Libman I; Schwartz AM; Gillo-Joffroy L; Barbeau A
    Can Psychiatr Assoc J; 1972 Apr; 17(2):123-31. PubMed ID: 5036506
    [No Abstract]   [Full Text] [Related]  

  • 22. [Results of treatment of Parkinsonism with L-dopa].
    De Divitiis E; D'Andrea F; Signorelli CD
    Sist Nerv; 1970; 22(2):99-108. PubMed ID: 5504563
    [No Abstract]   [Full Text] [Related]  

  • 23. L-dopa for postencephalitic Parkinsonism.
    Krasner N; Cornelius JM
    Br Med J; 1970 Nov; 4(5733):496. PubMed ID: 5481239
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa and related drugs.
    Med Lett Drugs Ther; 1973 Mar; 15(5):21-3. PubMed ID: 4697470
    [No Abstract]   [Full Text] [Related]  

  • 25. [L-dopa treatment of persons with parkinsonism in a hospital for geriatric rehabilitation].
    Antonini F; Baroni A; Roveyaz L
    Sist Nerv; 1970; 22(2):74-81. PubMed ID: 5504560
    [No Abstract]   [Full Text] [Related]  

  • 26. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 27. Side effects of L-dopa treatment.
    Greenburg J
    Pa Med; 1971 Apr; 74(4):55-6. PubMed ID: 5147645
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychosis and other psychiatric manifestations of levodopa therapy.
    Celesia GG; Barr AN
    Arch Neurol; 1970 Sep; 23(3):193-200. PubMed ID: 5456717
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa.
    Godwin-Austen RB; Bergmann S; Frears CC
    Br Med J; 1971 Nov; 4(5786):522-4. PubMed ID: 4942463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
    Parkes JD; Baxter RC; Marsden CD; Rees JE
    J Neurol Neurosurg Psychiatry; 1974 Apr; 37(4):422-6. PubMed ID: 4838913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse reactions during treatment of Parkinson's disease with levodopa.
    Martin WE
    JAMA; 1971 Jun; 216(12):1979-83. PubMed ID: 5314258
    [No Abstract]   [Full Text] [Related]  

  • 33. An evaluation of L-dopa in Parkinson patients.
    Mones RJ
    Trans Am Neurol Assoc; 1969; 94():307-9. PubMed ID: 5374472
    [No Abstract]   [Full Text] [Related]  

  • 34. Response of patients with postencephalitic Parkinsonism to levodopa.
    Duvoisin RC; Lobo-Antunes J; Yahr MD
    J Neurol Neurosurg Psychiatry; 1972 Aug; 35(4):487-95. PubMed ID: 5049808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 36. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A; Mars H; Botez MI; Joubert M
    Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of levodopa in the severely disabled patient.
    Sacks OW; Messeloff CR; Schwartz WF
    JAMA; 1970 Sep; 213(13):2270. PubMed ID: 5468938
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
    Parkes JD; Baxter RC; Curzon G; Knill-Jones RP; Knott PJ; Marsden CD; Tattersall R; Vollum D
    Lancet; 1971 May; 1(7709):1083-6. PubMed ID: 4102620
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
    Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
    [No Abstract]   [Full Text] [Related]  

  • 40. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.